PeptiDream Inc. (4587.T)
JPY 2018.5
(1.74%)
JPY 2018.5
(1.74%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 9.68 Billion JPY | 6.07% |
| 2022 | 9.13 Billion JPY | 252.66% |
| 2021 | 2.58 Billion JPY | 2.04% |
| 2020 | 2.53 Billion JPY | 4.21% |
| 2019 | 2.43 Billion JPY | 22.65% |
| 2018 | 1.98 Billion JPY | 14.29% |
| 2017 | 1.73 Billion JPY | 66.16% |
| 2016 | 1.04 Billion JPY | 50.76% |
| 2015 | 693.5 Million JPY | 91.72% |
| 2014 | 361.73 Million JPY | 19.47% |
| 2013 | 302.77 Million JPY | 21.17% |
| 2012 | 249.87 Million JPY | 108.66% |
| 2011 | 119.75 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 2.7 Billion JPY | 5.15% |
| 2024 Q1 | 2.57 Billion JPY | -12.95% |
| 2023 Q1 | 2.41 Billion JPY | -24.15% |
| 2023 Q2 | 2.53 Billion JPY | 4.81% |
| 2023 Q3 | 2.52 Billion JPY | -0.08% |
| 2023 Q4 | 2.95 Billion JPY | 16.79% |
| 2023 FY | 9.68 Billion JPY | 6.07% |
| 2022 FY | 9.13 Billion JPY | 252.66% |
| 2022 Q4 | 3.18 Billion JPY | 34.49% |
| 2022 Q2 | 582.14 Million JPY | -46.62% |
| 2022 Q1 | 1.09 Billion JPY | 22.89% |
| 2022 Q3 | 2.36 Billion JPY | 306.79% |
| 2021 Q4 | 887.47 Million JPY | 52.34% |
| 2021 FY | 2.58 Billion JPY | 2.04% |
| 2021 Q2 | 2.48 Billion JPY | 373.56% |
| 2021 Q3 | 582.57 Million JPY | -76.6% |
| 2021 Q1 | 525.73 Million JPY | -46.95% |
| 2020 Q1 | 536.29 Million JPY | 0.0% |
| 2020 FY | 2.53 Billion JPY | 4.21% |
| 2020 Q4 | 991.06 Million JPY | 101.94% |
| 2020 Q3 | 490.77 Million JPY | -5.6% |
| 2020 Q2 | 519.89 Million JPY | -3.06% |
| 2019 Q1 | 478.31 Million JPY | 12.17% |
| 2019 Q2 | 684.25 Million JPY | 43.05% |
| 2019 FY | 2.43 Billion JPY | 22.65% |
| 2019 Q3 | 485.61 Million JPY | -29.03% |
| 2018 Q2 | 373.71 Million JPY | 15.86% |
| 2018 Q3 | 396.61 Million JPY | 6.13% |
| 2018 Q1 | 322.56 Million JPY | 22.71% |
| 2018 Q4 | 426.4 Million JPY | 7.51% |
| 2018 FY | 1.98 Billion JPY | 14.29% |
| 2017 FY | 1.73 Billion JPY | 66.16% |
| 2017 Q4 | 262.87 Million JPY | -66.22% |
| 2017 Q3 | 778.13 Million JPY | 79.69% |
| 2017 Q2 | 433.04 Million JPY | 63.92% |
| 2017 Q1 | 264.18 Million JPY | 53.6% |
| 2016 FY | 1.04 Billion JPY | 50.76% |
| 2016 Q3 | 176.31 Million JPY | -17.53% |
| 2016 Q4 | 171.98 Million JPY | -2.45% |
| 2016 Q2 | 213.78 Million JPY | 5.67% |
| 2016 Q1 | 202.32 Million JPY | 37.75% |
| 2015 Q3 | 130.53 Million JPY | 6.05% |
| 2015 FY | 693.5 Million JPY | 91.72% |
| 2015 Q2 | 123.08 Million JPY | 53.0% |
| 2015 Q1 | 80.45 Million JPY | 7.31% |
| 2015 Q4 | 146.87 Million JPY | 12.52% |
| 2014 Q1 | 77.68 Million JPY | 14.1% |
| 2014 Q4 | 74.97 Million JPY | -9.91% |
| 2014 Q3 | 83.21 Million JPY | 16.21% |
| 2014 Q2 | 71.61 Million JPY | -7.82% |
| 2014 FY | 361.73 Million JPY | 19.47% |
| 2013 FY | 302.77 Million JPY | 21.17% |
| 2013 Q2 | 83.13 Million JPY | 0.0% |
| 2013 Q3 | 85.38 Million JPY | 2.71% |
| 2013 Q4 | 68.08 Million JPY | -20.26% |
| 2012 FY | 249.87 Million JPY | 108.66% |
| 2011 FY | 119.75 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -654.182% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -1579.44% |
| GNI Group Ltd. | 9.32 Billion JPY | -3.915% |
| Linical Co., Ltd. | 2.7 Billion JPY | -258.099% |
| Trans Genic Inc. | 2.15 Billion JPY | -348.52% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -549.647% |
| Soiken Holdings Inc. | 3.07 Billion JPY | -215.436% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | -421.669% |
| AnGes, Inc. | 8.9 Billion JPY | -8.819% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -927.193% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 49.519% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -2245.641% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -893.188% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | -277.292% |
| CanBas Co., Ltd. | 278 Million JPY | -3384.627% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -748.617% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | -432.867% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | -504.033% |
| Kidswell Bio Corporation | 2.37 Billion JPY | -308.046% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | -394.099% |
| Ribomic Inc. | 1.1 Billion JPY | -776.128% |
| SanBio Company Limited | 4.53 Billion JPY | -113.423% |
| Healios K.K. | 3.48 Billion JPY | -177.811% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -738.914% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -625.929% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -590.24% |
| StemRIM | 2.07 Billion JPY | -366.631% |
| CellSource Co., Ltd. | 1.96 Billion JPY | -393.368% |
| FunPep Company Limited | 313.82 Million JPY | -2986.876% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -911.184% |
| Stella Pharma Corporation | 963.98 Million JPY | -904.919% |
| TMS Co., Ltd. | 943.25 Million JPY | -927.006% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -788.779% |
| Cuorips Inc. | 598.11 Million JPY | -1519.624% |
| K Pharma,Inc. | 543.94 Million JPY | -1680.937% |
| Takara Bio Inc. | 23.9 Billion JPY | 59.476% |
| ReproCELL Incorporated | 1.51 Billion JPY | -539.839% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -718.188% |
| StemCell Institute Inc. | 1.16 Billion JPY | -733.584% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | -536.367% |
| CellSeed Inc. | 804.93 Million JPY | -1103.49% |